Evidence map›Paper›PMID 32139701›Full record

ArticleNature communications2020

Primary tumors release ITGBL1-rich extracellular vesicles to promote distal metastatic tumor growth through fibroblast-niche formation.

Qing Ji, Lihong Zhou, Hua Sui, Liu Yang, Xinnan Wu, Qing Song, Ru Jia, Ruixiao Li, Jian Sun, Ziyuan Wang and 10 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 183 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
183citing papers in PubMed, 3 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

183 citing papers in PubMed, 3 syntheses or guidelines pooled it, 281 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

123 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 3 countries.

Qing Ji *Department of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Lihong Zhou *Department of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Hua Sui *Department of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Liu YangDepartment of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Xinnan WuDepartment of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Qing SongDepartment of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Ru JiaDepartment of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Ruixiao LiDepartment of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Jian SunDepartment of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Ziyuan WangDepartment of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Ningning LiuDepartment of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Yuanyuan FengDepartment of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Xiaoting SunDepartment of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Gang CaiDepartment of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Yu FengDepartment of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Jianfeng CaiDepartment of Chemistry, University of South Florida, Tampa, FL, 33620, USA.
Yihai CaoAcademy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China.
Guoxiang CaiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, 200032, Shanghai, China. gxcai@fudan.edu.cn.
Yan WangDepartment of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China. wangyan_sg@126.com.
Qi LiDepartment of Medical Oncology and cancer institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China. qili@shutcm.edu.cn.
Shanghai University of Traditional Chinese Medicine · CNShuguang Hospital · CNKarolinska Institutet · SEUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor metastasis is a hallmark of cancer. Metastatic cancer cells often reside in distal tissues and organs in their dormant state. Mechanisms underlying the pre-metastatic niche formation are poorly understood. Here we show that in a colorectal cancer (CRC) model, primary tumors release integrin beta-like 1 (ITGBL1)-rich extracellular vesicles (EVs) to the circulation to activate resident fibroblasts in remote organs. The activated fibroblasts induce the pre-metastatic niche formation and promote metastatic cancer growth by secreting pro-inflammatory cytokine, such as IL-6 and IL-8. Mechanistically, the primary CRC-derived ITGBL1-enriched EVs stimulate the TNFAIP3-mediated NF-κB signaling pathway to activate fibroblasts. Consequently, the activated fibroblasts produce high levels of pro-inflammatory cytokines to promote metastatic cancer growth. These findings uncover a tumor-stromal interaction in the metastatic tumor microenvironment and an intimate signaling communication between primary tumors and metastases through the ITGBL1-loaded EVs. Targeting the EVs-ITGBL1-CAFs-TNFAIP3-NF-κB signaling axis provides an attractive approach for treating metastatic diseases.

Indexed as

AnimalsCancer-Associated FibroblastsCarcinogenesisCell Line, TumorCell MovementColorectal NeoplasmsCore Binding Factor Alpha 1 SubunitDisease ProgressionEpithelial-Mesenchymal TransitionExtracellular VesiclesFibroblastsGene Expression Regulation, NeoplasticHumansIntegrin beta1LuciferasesMiceCore Binding Factor Alpha 1 SubunitIntegrin beta1ITGBL1 protein, humanLuciferasesNF-kappa BTNFAIP3 protein, humanTumor Necrosis Factor alpha-Induced Protein 3

Identifiers

PMID32139701
PMCPMC7058049
OpenAlexW3010606541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.